With over-the-counter birth control pills headed to pharmacy shelves early next year, big questions remain about costs and accessibility, according to new research from health-policy research nonprofit KFF.
When the U.S. Food and Drug Administration in July approved the first daily over-the-counter birth control pill, Perrigo Co. PLC’s PRGO Opill, reproductive health researchers and advocacy groups emphasized that equitable access would depend on pricing and insurance coverage. But the KFF report released Thursday highlighted…
Read the full article here
